Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 18;14(1):8991.
doi: 10.1038/s41598-024-59442-4.

Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro)

Affiliations

Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro)

Pedro Henrique R de A Azevedo et al. Sci Rep. .

Abstract

COVID-19 is a multisystemic disease caused by the SARS-CoV-2 airborne virus, a member of the Coronaviridae family. It has a positive sense single-stranded RNA genome and encodes two non-structural proteins through viral cysteine-proteases processing. Blocking this step is crucial to control virus replication. In this work, we reported the synthesis of 23 statine-based peptidomimetics to determine their ability to inhibit the main protease (Mpro) activity of SARS-CoV-2. Among the 23 peptidomimetics, 15 compounds effectively inhibited Mpro activity by 50% or more, while three compounds (7d, 8e, and 9g) exhibited maximum inhibition above 70% and IC50 < 1 µM. Compounds 7d, 8e, and 9g inhibited roughly 80% of SARS-CoV-2 replication and proved no cytotoxicity. Molecular docking simulations show putative hydrogen bond and hydrophobic interactions between specific amino acids and these inhibitors. Molecular dynamics simulations further confirmed the stability and persisting interactions in Mpro's subsites, exhibiting favorable free energy binding (ΔGbind) values. These findings suggest the statine-based peptidomimetics as potential therapeutic agents against SARS-CoV-2 by targeting Mpro.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Synthesis of the β-hydroxy-γ-amino acid intermediate (1).
Figure 2
Figure 2
Synthesis of the statine-based peptidomimetics (7a-h, 8a-g, 9a-g, and 10).
Figure 3
Figure 3
The dose-dependent curves of the statine-based peptidomimetics 7d, 8e, and 9g (and atazanavir, ATV, as positive control) against SARS-CoV-2. Calu-3 cells infected with SARS-CoV-2 MOI 0.01 were treated with the compounds 7d, 8e, 9g, and ATV at a semi-log curve of concentration (10, 3.16, 1, 0.316, and 0.1 µM) for 24 h at 37 ºC, 5% CO2 (n = 3).
Figure 4
Figure 4
Best pose by molecular docking simulations of statine-like derivatives on the SARS-CoV-2 Mpro active site (PDB ID: 6LU7): (A) 7d; (B) 8e, and (C) 9g. The residues involved in H-bond interactions (dashed black lines) with the ligands are in ball-and-line model (cyan color) and residues involved in hydrophobic interactions are in stick models (light green color). In 2D structures, the atoms (or groups) of the ligands involved in H-bond interactions are circled in yellow.
Figure 5
Figure 5
RMSD analysis of the 7d (A), 8e (B), and 9g (C) relative to the Mpro-Cα atoms.
Figure 6
Figure 6
Cα-RMSD analysis per Mpro subsites S1 + S1’ (red line), S2 (green line), S4 (purple line), and S5 (blue line) that are relative to the simulations by molecular dynamics of the ligand-Mpro complex. Ligands: 7d (A), 8e (B), and 9g (C).
Figure 7
Figure 7
Cα-RMSF analysis at different times relative to the simulations by molecular dynamics of the ligand-Mpro complex. Ligands: 7d (A), 8e (B) and 9g (C).

Similar articles

Cited by

References

    1. WHO; World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (2023).
    1. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155–170. doi: 10.1038/s41579-020-00468-6. - DOI - PMC - PubMed
    1. Hilgenfeld R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085–4096. doi: 10.1111/febs.12936. - DOI - PMC - PubMed
    1. NIH; National Institutes of Health. COVID-19 Treatment Guidelines. 2023https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/what.... - PubMed
    1. Mohapatra S, et al. Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking. PLoS One. 2020;15:e0241543. doi: 10.1371/journal.pone.0241543. - DOI - PMC - PubMed